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Mitogen-activated protein (MAP) kinases can be
grouped into three structural families, ERK, JNK, and
p38, which are thought to carry out unique functions
within cells. We demonstrate that ERK, JNK, and p38
are activated by distinct combinations of stimuli in T
cells that simulate full or partial activation through the
T cell receptor. These kinases are regulated by reversi-
ble phosphorylation on Tyr and Thr, and the dual spe-
cific phosphatases PAC1 and MKP-1 previously have
been implicated in the in vivo inactivation of ERK or of
ERK and JNK, respectively. Here we characterize a new
MAP kinase phosphatase, MKP-2, that is induced in hu-
man peripheral blood T cells with phorbol 12-myristate
13-acetate and is expressed in a variety of nonhemato-
poietic tissues as well. We show that the in vivo sub-
strate specificities of individual phosphatases are
unique. PAC1, MKP-2, and MKP-1 recognize ERK and
p38, ERK and JNK, and ERK, p38, and JNK, respectively.
Thus, individual MAP kinase phosphatases can differen-
tially regulate the potential for cross-talk between the
various MAP kinase pathways. A hyperactive allele of
ERK2 (D319N), analogous to the Drosophila sevenmaker
gain-of-function mutation, has significantly reduced
sensitivity to all three MAP kinase phosphatases in vivo.
Mitogen-activated protein (MAP)1 kinases are activated by
dual phosphorylation on Tyr and Thr, and they are important
in mediating signal transduction from the cell surface to the
nucleus (1). Several MAP kinase signal transduction pathways
have been molecularly characterized (for reviews, see Refs.
2–6). In yeast, at least four genetically distinct, functionally
independent, MAP kinase-mediated signaling pathways have
been defined (3, 4).
In mammals, three structural families of MAP kinases have
been identified that have distinct substrate specificities (4–6).
The members of one family, ERK1 and ERK2, which are most
closely related to yeast FUS3 and KSS1, are activated by
growth and differentiation factors and by phorbol esters (7).
The JNK family (also known as SAPK) and p38 MAP kinase
(which is the closest structural homolog of the yeast HOG1) are
activated either in common or parallel pathways by proinflam-
matory cytokines and environmental stress and to a lesser
extent by growth factors such as EGF (8). Some stimuli, such as
T cell receptor ligation and short wavelength ultraviolet light
treatment, activate both ERK and JNK pathways (9, 10).
ERK, JNK, and p38 are regulated by reversible dual phos-
phorylation within the motifs TEY, TPY, and TGY, respectively
(5). ERK2 has been shown to be dephosphorylated in vitro and
in vivo on Thr and Tyr by the nuclear localized phosphatases
PAC1 (11) and MKP-1 (12). In addition, JNK appears to be a
target for MKP-1 (10). PAC1 and MKP-1 share highly homol-
ogous C-terminal catalytic domains but display relatively
unique domains at their N termini, which may be involved in
substrate recognition or possibly may be important in some
aspects of post-translational regulation such as regulated pro-
teolysis (13). PAC1 is expressed predominantly in hematopoi-
etic cells, absent in quiescent cells, and transcriptionally in-
duced within minutes following antigen receptor ligation or
treatment with phorbol ester (13). MKP-1 is expressed in a
wide variety of tissues and induced by growth factors and
genotoxic and environmental stresses (10, 14, 15).
Recently, two additional MAP kinase phosphatases, hVH3
(16) (also known as B23 (17)) and MKP-2 (18) (also known as
hVH2 (19)), have been isolated by virtue of their structural
homology to PAC1 and MKP-1. MKP-2 and hVH3 display
highly conserved catalytic and more distantly related N-termi-
nal domains with PAC1 and MKP-1. MKP-2 and hVH3 have
been shown to dephosphorylate ERK2 (16–19). PAC1, MKP-1,
hVH3, and MKP-2 are early response genes that have unique
but overlapping tissue distributions (13, 15, 19). In order to
begin dissecting the biological roles played by the related phos-
phatases PAC1, MKP-1, and MKP-2, we have determined in
fine detail their in vivo substrate specificity for the three fam-
ilies of MAP kinases.
EXPERIMENTAL PROCEDURES
Materials—Phorbol 12-myristate 13-acetate and phytohemaggluti-
nin were from Sigma; EGF and tumor necrosis factor a were from
Peprotech; rabbit anti-ERK2 antibodies were from Upstate Biotechnol-
ogy, Inc., and anti-CD3 monoclonal antibody was from Boehringer
Mannheim. pMT2T-HA-p54b (JNK2) was provided by J. R. Woodgett
(Ontario Cancer Institute); and pCEV-HA-HOG (p38), pcDNA3-
HA-ERK2, GST-c-Jun-(1–79) and GST-ATF2-(1–96) plasmids were pro-
vided by J. S. Gutkind (NIDR, National Institutes of Health). Plasmids
expressing PAC1, MKP-1, and MKP-2 were constructed by inserting
their cDNA fragments into pMT2T. The polymerase chain reaction
fragment of human ERK2 was cloned into the BamHI site of pCGN-
Hygro, and its sevenmaker gain-of-function mutation was made by
replacing the Asp residue corresponding to codon 319 with an Asn
residue.
Cell Culture and Transfection—COS-7, NIH3T3, and HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium containing 10%
fetal calf serum and transfected by using lipofectamine (Life Technol-
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ogies, Inc.) according to the manufacturer’s protocol. Jurkat cells were
maintained in RPMI 1640 medium supplemented with 10% fetal calf
serum and transfected by using electroporation. Forty-eight h after
transfection, cells were serum starved for 30 min and then stimulated
as indicated.
MAP Kinases Assay—The stimulated cell lysates were prepared as
described (11). The HA-tagged kinase was immunoprecipitated with
monoclonal antibody 12CA5 directed against the HA epitope (20). The
immunocomplex kinase assay was performed as described (21) using
individual kinase substrates as indicated. After SDS-polyacrylamide
gel electrophoresis, phosphorylated proteins were visualized by
autoradiography.
Metabolic Labeling, Immunoprecipitation, and Western Blotting—
Human peripheral blood T cells were purified and metabolically labeled
as described previously (13). Cell lysates were prepared as above. The
use of monoclonal and polyclonal antibodies against PAC1 has been
described (13). MKP-2 was immunoprecipitated for 4 h with affinity-
purified rabbit antibodies (13) directed against MKP-2 peptides (encom-
passing amino acids 12–27 and 128–142). The immunoprecipitates
were subjected to SDS-polyacrylamide gel electrophoresis followed by
either autoradiography or Western blotting.
In order to determine expression of HA-ERK2 and mutant HA-
ERK2(D319N), cell lysates were immunoprecipitated for 2 h with the
specific antibody 12CA5. The immunoprecipitates were analyzed by
Western blots with enhanced chemiluminescence detection (Amersham
Corp.) using rabbit anti-ERK2 antibodies.
RESULTS
Previous work by us (22) and others (23) has shown that
there is an extended family of genes with homology to the MAP
kinase phosphatases PAC1 and MKP-1. Using low stringency
hybridization of a PAC1 coding region probe, we isolated and
characterized a MAP kinase phosphatase-like gene from a hu-
man, mitogen-activated T cell cDNA library (24). Because this
gene was most closely related to MKP-1 and the encoded pro-
tein had in vivoMAP kinase phosphatase activity, we named it
MAP kinase phosphatase 2 (MKP-2). During preparation of
this paper, the sequences of hVH2 and rat mkp-2 were pub-
lished (18, 19). hVH2 is identical in the encoded amino acid
sequence to our human MKP-2 and varies in 20 out of a total of
2368 nucleotide residues (see GenBanky accession numbers
U21108 and U48807). Rat MKP-2 is 89% homologous to human
MKP-2 and unrelated between amino acids 97 and 131 due to
a frameshift in the rat gene relative to humanMKP-2 and other
MAP kinase phosphatases (16, 17).
Northern blot analyses demonstrated a low but detectable
level of MKP-2 mRNA in resting human peripheral blood T
cells that was induced approximately 5-fold following stimula-
tion by phorbol 12-myristate 13-acetate for 1 or 3 h (not shown).
Two mRNA species of 6.0 and 2.3 kilobases were detected using
an MKP-2-specific 39-untranslated region probe (see Fig. 2).
Because the probe detects a single gene in Southern blot anal-
yses (not shown), the two mRNA species appear to result from
alternative splicing or differential use of polyadenylation sites.
MKP-2 encodes a protein of 394 amino acids with a predicted
molecular mass of 42.9 kDa. In order to verify the deduced
sequence of MKP-2, we prepared anti-peptide antibodies,
which were used to immunoprecipitate extracts derived from
either resting or phorbol 12-myristate 13-acetate-activated,
metabolically labeled human peripheral blood T cells (Fig. 1).
The anti-peptide antibodies precipitated an easily detectable
42 kDa protein from activated but not resting peripheral blood
T cells. The endogenous MKP-2 protein from peripheral blood T
cells migrated identically to the protein specifically precipi-
tated from extracts of COS-7 cells transfected with an MKP-2
expression vector (not shown).
In order to determine the tissue specificity ofMKP-2 expres-
sion, we probed Northern blots of multiple human tissue
poly(A)1 RNAs. As shown in Fig. 2, all of the 13 tissues exam-
ined expressed some level of MKP-2 mRNA. Both 6.0- and
2.3-kilobase MKP-2 mRNA species were expressed in all tis-
sues, but the relative concentration of the 2.3-kilobase band
was higher in testis than other tissues. Prostate, testis, pan-
creas, adrenal cortex, and stomach displayed the highest rela-
tive levels. Common features of these tissues include a predom-
FIG. 3. Protein expression is proportional to the amount of
PAC1 cDNA transfected in HeLa cells. HeLa or COS cells were
grown and transfected with different amounts of PAC1 cDNA plasmid
as indicated at the top of the figure. Forty-eight h after transfection the
cells were harvested and extracts were made as described under “Ex-
perimental Procedures.” Extracts of HeLa cells (5.6 mg of proteins) and
COS cells (1.2 mg of proteins) were immunoprecipitated with a mixture
of monoclonal antibodies (P9D10, P10C5, and P12B11) directed against
PAC1. The immunoprecipitates were analyzed by Western blots with
enhanced chemiluminescence detection (Amersham Corp.) using affin-
ity-purified rabbit anti-PAC1 antibodies.
FIG. 1. MKP-2 induction in human T cells. Human peripheral
blood T cells were stimulated with phorbol 12-myristate 13-acetate (50
ng/ml) and phytohemagglutinin (1 mg/ml) and metabolically labeled
with [35S]methionine and [35S]cysteine for 1 h prior to harvesting.
Cellular extracts were immunoprecipitated with a mixture of antibod-
ies directed against MKP-2 peptides (encompassing amino acids 12–27
and 128–142). The immunoprecipitates were subjected to SDS-poly-
acrylamide gel electrophoresis and autoradiography. Stimulation times
(in h) are shown above each lane. Molecular mass makers are shown in
the left margin in kDa.
FIG. 2. MKP-2 is widely expressed in human tissues. Human
multiple tissue poly(A)1 RNA blots (Clontech) were probed with a
fragment corresponding to the 39-untranslated region of MKP-2 (nucle-
otides 1203–2241, GenBanky accession number U48807) by using the
QuickHyb method (Stratagene). RNA markers (in kilobases) are shown
in the left margin. PBL, peripheral blood leukocytes.
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inantly epithelial cell population and hormone responsiveness.
Hormones such as cholecystokinin/gastrin (25, 26) that act
upon pancreatic acini, gastrointestinal tract, and central nerv-
ous system, and angiotensin II (27) that acts upon adrenocor-
tical cells have been shown to activate the ERK pathway upon
binding to their receptors. It will be interesting to determine
whether MKP-2 RNA induction is responsive to appropriate
hormones in these tissues. Unlike MKP-1 and hVH3 (B23) (16,
17),MKP-2 is not expressed following mitogenic or stress stim-
ulation of human fibroblasts (not shown).
PAC1 and MKP-2 are expressed in T cells with overlapping
kinetics following stimulation with phorbol 12-myristate 13-
acetate. What might the distinct roles of these proteins be? We
considered fine substrate recognition to be a likely possibility.
Therefore, we assayed the relative ability of MKP-2, PAC1, and
MKP-1 to dephosphorylate ERK2 and the other related MAP
kinases, JNK2 and p38. COS-7, HeLa, and NIH3T3 cells were
cotransfected with DNA encoding an epitope-tagged kinase and
various concentrations of DNA encoding one of the MAP kinase
phosphatases. As shown for PAC1 expression in HeLa cells, the
transfection conditions used here resulted in a linear relation-
ship between the amount of DNA transfected and the conse-
quent levels of protein expression (Fig. 3). Following stimula-
tion of the cells, the level of kinase activity achieved in the
constitutive presence of the various MAP kinase phosphatases
was determined.
Fig. 4A shows the activity of immunoprecipitated ERK2 fol-
lowing EGF stimulation as determined by myelin basic protein
phosphorylation. COS-7 cells, which greatly overexpress the
transfected proteins, demonstrated virtually complete inacti-
vation of ERK2. However, the COS-7 system is not a good
reflection of physiological MAP kinase phosphatase concentra-
tions. Western blot quantitation of immunoprecipitated cellu-
lar extracts from cells transfected with PAC1 demonstrated
that COS-7 cells expressed in excess of 1000 times more PAC1
than equivalently transfected HeLa cells (Fig. 3). As shown for
HeLa cells in Fig. 4A, PAC1, MKP-1, and MKP-2 demonstrated
similar degrees of ERK2 phosphatase activity that were in a
titratable range. PAC1 had somewhat less activity in NIH3T3
cells relative to MKP-1 and MKP-2, which is probably a result
of the instability of PAC1 in serum-starved NIH3T3 cells (not
shown).
Following tumor necrosis factor a treatment of cells, the
kinase activity of immunoprecipitated JNK2 was determined
by its ability to phosphorylate the N-terminal fragment (1–79)
of c-Jun (Fig. 4B). MKP-1 had robust, titratable activity
against JNK2. MKP-2 had detectable activity against JNK2,
although full inactivation of JNK2 was not observed even at the
higher phosphatase concentration. Finally, PAC1 appeared to
be inactive against JNK2 in NIH3T3 and HeLa cells and had
minimal activity in COS-7 cells.
A third pattern of substrate specificity is seen in Fig. 4C,
which shows the activity of immunoprecipitated p38 following
arsenite treatment as assayed by the phosphorylation of the
N-terminal fragment (1–96) of ATF2. All three phosphatases
demonstrated activity against p38 in the COS-7 system. In
NIH3T3 and HeLa cells MKP-1 was highly active against p38,
FIG. 4. PAC1, MKP-1, and MKP-2 have distinct substrate spec-
ificities. COS-7, NIH3T3, or HeLa cells were cotransfected with HA-
ERK2 (A), HA-JNK2 (B), or HA-p38 (C) expression plasmids (0.4 mg)
and PAC1, MKP-1, or MKP-2 expression plasmid (0.4 mg or 1.6 mg as
indicated). After 48 h cells cotransfected with HA-ERK2 DNA were
stimulated with EGF (25 ng/ml) for 5 min. Immunopurified HA-ERK2
was assayed for kinase activity by using myelin basic protein as a
substrate. Cells cotransfected with HA-JNK2 DNA were stimulated
with tumor necrosis factor a (TNFa) (50 ng/ml) for 15 min, and the
activity of the immunopurified HA-JNK2 was measured by phospho-
rylation of GST-c-Jun-(1–79). Cells cotransfected with HA-p38 plasmid
were stimulated with sodium arsenite (0.5 mM) for 30 min. Activity of
the immunopurified HA-p38 was measured by using GST-ATF2-(1–96)
as a substrate. The relative kinase activity was quantitated based on
the activity present in unstimulated cells cotransfected with the MAP
kinase plasmid and empty pMT2T.
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while PAC1 showed moderate levels of titratable activity.
MKP-2 had virtually no activity against p38 in NIH3T3 and
HeLa cells, indicating that activity toward p38 is observed only
at high, nonphysiological concentrations of MKP-2. In consid-
ering all three substrates, each individual phosphatase showed
a unique pattern of substrate specificity.
We examined the activity of PAC1, MKP-1, and MKP-2 to-
ward a hyperactive mutant of mammalian ERK2 (D319N
ERK2) that is analogous to the Drosophila sevenmaker gain-of-
function mutation (28) and contains a substitution of Asn for
Asp at position 319. D319N ERK2 does not have constitutive
kinase activity in vitro but instead appears to be more highly
responsive to activation (29), possibly as a result of decreased
sensitivity to phosphatases. In order to determine the sensitiv-
ity of D319N ERK2 to MAP kinase phosphatases in vivo, we
utilized the cotransfection system described above. As shown in
Fig. 5A, D319N ERK2 was resistant to inactivation by levels of
PAC1, MKP-1, and MKP-2 that inactivated wild type ERK2 to
near background levels. This effect was not due to increased
expression of D319N ERK2 relative to that of wild type ERK2
as demonstrated by Western blotting of epitope-tagged ERK2
and D319N ERK2 (Fig. 5B). In addition, EGF-stimulated in-
creases in D319N ERK2 activity were completely eliminated in
COS-7 cells that had been cotransfected with a MAP kinase
phosphatase (Fig. 5C), demonstrating the sensitivity of the
sevenmakermutation at sufficiently highMAP kinase phospha-
tase concentrations.
In order to address the potential physiological function of the
MAP kinase phosphatases induced in T cells, we determined
whether there is a correlation between the stimuli that activate
the different kinases and the stimuli that induce the phos-
phatases. PAC1 and MKP-2 are induced within the 1st h after
activating T cells with mitogens (Fig. 1 and Ref. 13) or T cell
receptor (TCR) ligation (30). We have been unable to detect
MKP-1 protein in activated T cells. Stress stimuli (including
short wavelength ultraviolet light, arsenite, and hyperosmolar-
ity) that activate the JNK and p38 kinases did not induce PAC1
or MKP-2 in T cells (not shown). Previous results have shown
that ERK2 and JNK1 are activated following T cell activation
(9). Therefore, we investigated the range of stimuli that induce
p38, ERK, and JNK activation in T cells.
We assayed the catalytic activation of epitope-tagged, trans-
fected ERK2, JNK2, and p38 in Jurkat cells following various
types of stimulation. a-CD3 binds the TCR and is partially
stimulatory, while the combination of phorbol 12-myristate
13-acetate and ionomycin mimics co-stimulation through the
TCR and accessory molecules. As shown in Fig. 6A, ERK2 was
maximally activated with phorbol 12-myristate 13-acetate
alone, consistent with the previous results (31), and the condi-
tions of a-CD3 stimulation used here were nonactivating for
ERK2. A different pattern of activation was seen with JNK2
(Fig. 6B). JNK2 was weakly stimulated by phorbol 12-myris-
tate 13-acetate alone, stimulated to a greater extent with phor-
bol 12-myristate 13-acetate in combination with a-CD3 or phy-
tohemagglutinin, and maximally stimulated by co-stimulation
with phorbol 12-myristate 13-acetate and ionomycin. p38 was
activated by TCR ligation in a manner distinct from ERK and
JNK (Fig. 6C). p38 was not activated by phorbol 12-myristate
13-acetate alone, was stimulated to near maximal activity with
a-CD3, and was stimulated maximally by the combination of
phorbol 12-myristate 13-acetate and ionomycin or a-CD3.
DISCUSSION
MAP kinase phosphatases form a family characterized by
highly structurally related catalytic domains of approximately
15 kDa (32). The known MAP kinase phosphatases are early
response genes and have unique but highly overlapping tissue
distributions (13, 15, 19). We show here that PAC1, MKP-1,
and MKP-2 have distinct patterns of substrate specificity.
MKP-1-inactivated ERK2, JNK2, and p38 equally. PAC1 did
FIG. 5. Mutant ERK2(D319N) is less sensitive to inactivation
by MAP kinase phosphatases in vivo. HA-ERK2 or mutant HA-
ERK2(D319N) expression plasmid (1.25 mg) was cotransfected into cells
with PAC1, MKP-1, or MKP-2 expression plasmid (10 mg). After 48 h
transfected cells were stimulated with EGF (25 ng/ml) for 5 min. A,
ERK2 activity was measured in transfected HeLa cells. The kinase
activity was measured by immunocomplex kinase assays with myelin
basic protein (MBP) (5 mg) as a substrate. The relative kinase activity
was quantitated based on the activity present in unstimulated cells. B,
Western blotting of ERK2 in transfected HeLa cells is shown. The
12CA5 immunoprecipitates were subjected to Western blotting using
rabbit anti-ERK2 antibodies. C, ERK2 activity was measured in trans-
fected COS-7 cells as described for A.
FIG. 6. ERK2, JNK2, and p38 kinase activity is induced by
immune stimulants in Jurkat cells. Jurkat cells were transfected
with HA-ERK2 (A), HA-JNK2 (B), or HA-p38 (C) plasmids by using
electroporation. After 48 h cells were stimulated as indicated with
tumor necrosis factor a (TNFa, 50 ng/ml), sodium arsenite (0.5 mM),
phorbol 12-myristate 13-acetate (PMA, 50 ng/ml), phytohemagglutinin
(PHA, 1 mg/ml), ionomycin (Ion, 2 mg/ml), anti-CD3 (10 mg/ml), or
combinations of the above as indicated. Activity of the HA-tagged ki-
nases was measured using immunocomplex kinase assays with sub-
strates as indicated. MBP, myelin basic protein.
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not inactivate JNK2, nor did MKP-2 inactivate p38. It is not
possible to make a statement about the relative specific activity
of the various phosphatases. However, it is clear that individ-
ual phosphatases demonstrated unique patterns of MAP ki-
nase recognition within a single cell system. In addition, the
results were consistent between NIH3T3 and HeLa cells. MAP
kinase phosphatases appear to exist in cells at low steady state
concentrations (11, 15) that were approximated by the trans-
fection conditions used here for NIH3T3 and HeLa cells. At
high concentrations of PAC1, MKP-1, and MKP-2 such as ex-
ists in transfected COS-7 cells, much of the substrate specific-
ity is lost (see Figs. 3–5).
We exploited the cotransfection system described above to
investigate the specificity of the various phosphatases toward a
hyperactive allele of ERK2 (D319N ERK2). The substitution of
Asn for Asp at position 319 of mammalian ERK2 is equivalent
to the Drosophila sevenmaker gain-of-function mutation.
D319N ERK2 demonstrated almost no sensitivity toward de-
phosphorylation by PAC1, MKP-1, or MKP-2 under conditions
that inactivated wild type ERK2 to background levels. D319 is
located on the exterior face of ERK2 on the opposite side of the
molecule from the phosphorylation lip and substrate binding
site (33). The substitution of Asn for Asp at position 319 has
been proposed to affect the structure or orientation of the N and
C domains (33). Interestingly, the D319N mutation does not
appear to greatly affect the catalytic activity of ERK2 or its
recognition by MAP kinase kinase (29). D319N ERK2 can be
dephosphorylated by the high concentrations of phosphatases
expressed in COS-7 cells in vivo (Fig. 5C) or by purified MKP-1
in vitro (29), suggesting that there is not an absolute structural
impediment to dephosphorylation. Therefore, most likely the
affinity of the MAP kinase phosphatases for D319N ERK2 is
sufficiently decreased to have a substantial effect in vivo.
T cell activation results in ERK, JNK, and p38 activation,
which is followed by induction of PAC1 and MKP-2 expression.
The three kinases are responsive to distinct combinations of
stimuli, suggesting the potential for differential regulation of
the kinase pathways in response to external signals in T cells.
Thus, various conditions of immune stimulation such as acti-
vation or tolerance induction may lead to differential activation
of ERK, JNK, and p38.
TCR-mediated stimulation activates multiple MAP kinase
pathways, as appears to be the case for short wavelength ul-
traviolet light treatment (9, 34) and probably a variety of other
stimuli as well. It seems likely that targets of the various MAP
kinase pathways will cooperate to affect gene expression or
other physiological responses to extracellular stimuli. Differen-
tial induction of the MAP kinase phosphatases in a cell type or
situation-specific manner appears to contribute an additional
level of regulation upon the relative activities of the various
MAP kinase pathways.
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